Alitretinoin

證據等級: L5

預測適應症: 10 個

Alitretinoin: From Chronic Hand Eczema to Acne

One-Sentence Summary

Alitretinoin (9-cis-retinoic acid, Toctino) is a pan-retinoid receptor agonist currently approved in the European Union for severe chronic hand eczema that is refractory to potent topical corticosteroids. The TxGNN model’s top-scored prediction — amenorrhea (99.99%) — has been assessed as Hold (Evidence Level L5: no supporting clinical data and no plausible therapeutic rationale); the most clinically actionable prediction is Acne (TxGNN score 99.92%, Evidence Level L3), supported by 5 publications and contextual trial data linking retinoid class pharmacology to sebaceous gland biology. However, since isotretinoin already occupies the severe acne treatment niche, a differentiated benefit for alitretinoin would need to be established before further development is warranted.

Quick Overview

Item	Content
Original Indication	Severe chronic hand eczema (refractory to potent topical corticosteroids)
Predicted New Indication	Acne
TxGNN Prediction Score	99.92%
Evidence Level	L3 (observational studies / mechanistic reviews)
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0 (national); EMA centralised authorisation exists as Toctino
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current Evidence Pack (classified as a data gap). Based on published pharmacology, Alitretinoin is the 9-cis isomer of retinoic acid and acts as a pan-retinoid agonist — binding and activating both retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXRα, RXRβ, RXRγ). This dual receptor activity distinguishes it from isotretinoin (13-cis-RA), which achieves its effects primarily through RAR pathways after metabolic conversion. Alitretinoin’s proven ability to reduce skin inflammation and normalise keratinocyte differentiation in chronic hand eczema reflects the same receptor biology that makes retinoids effective in acne.

Retinoids as a therapeutic class are well established in acne: isotretinoin is the gold standard for severe nodular acne, working through suppression of sebaceous gland secretion, normalisation of follicular hyperkeratinisation, and direct anti-inflammatory effects — all driven by RAR/RXR signalling. Because alitretinoin shares this mechanistic class, the TxGNN prediction is biologically plausible. A 1996 head-to-head experimental comparison (PMID 8884148) found that 9-cis-RA (alitretinoin) inhibited cultured human sebocyte proliferation and reduced sebaceous gland volume in animal models as effectively as 13-cis-RA (isotretinoin), providing the most direct mechanistic support available.

The key unresolved clinical question is not whether retinoids work in acne, but whether alitretinoin offers a differentiated advantage over isotretinoin — for example through its additional RXR agonism, a different tolerability profile, or a specific patient subgroup (e.g., concurrent hand eczema and acne, or isotretinoin-refractory patients). Without a direct clinical study addressing this, the prediction remains at the Research Question stage.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04663906	N/A	Unknown	300	Investigates whether oral isotretinoin (not alitretinoin) increases COVID-19 infection risk due to retinoid-induced nasal mucosal dryness. Not directly relevant to alitretinoin efficacy in acne; provides background on oral retinoid safety surveillance in a dermatology setting.

No clinical trials directly investigating alitretinoin for acne were identified. The single retrieved trial examines a related retinoid (isotretinoin) for an unrelated safety endpoint.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
8884148	1996	Clinical Comparison Trial	Dermatology (Basel)	Direct head-to-head comparison of alitretinoin (9-cis-RA) vs isotretinoin (13-cis-RA): equivalent inhibition of cultured human sebocyte proliferation and comparable reduction of sebaceous gland size in hamster models — strongest direct evidence supporting mechanistic plausibility for acne.
41692081	2026	Narrative Review	Clinics in Dermatology	Comprehensive review of vitamin A and retinoids in dermatology; alitretinoin is identified alongside isotretinoin, acitretin, and bexarotene as an established oral retinoid with recognised dermatological applications.
11586072	2001	Narrative Review	Skin Pharmacol Appl Skin Physiol	Reviews RAR/RXR nuclear receptor biology and the pleiotropic skin effects of retinoids; discusses mechanistic overlap between acne pathophysiology and retinoid target structures (sebaceous glands, follicular epithelium).
8884149	1996	Clinical Study	Dermatology (Basel)	Investigates the effect of oral all-trans-retinoic acid on sebum excretion rate; establishes sebum suppression as the critical predictive marker for oral retinoid anti-acne activity, providing a benchmark for evaluating alitretinoin.
10521699	1999	Mechanistic Review	Biochim Biophys Acta	Reviews retinoid binding proteins and metabolic enzymes; provides foundational mechanistic context for how 9-cis-RA (alitretinoin) is processed and activates nuclear receptors across epithelial and skin tissues.

Denmark Market Information

Alitretinoin is currently not marketed in Denmark based on Laegemiddelstyrelsen national authorisation records (0 national marketing authorisations on file).

Important clinical context: Alitretinoin is approved across the European Union via the EMA centralised procedure as Toctino (oral capsules, 10 mg and 30 mg) for the treatment of severe chronic hand eczema in adults that is refractory to treatment with potent topical corticosteroids. This EMA centralised marketing authorisation is legally valid in all EU Member States, including Denmark. However, national market presence (commercial availability and pharmacy dispensing) may differ from legal authorisation status. Clinicians in Denmark should verify actual availability with Laegemiddelstyrelsen or hospital pharmacy services before considering prescribing.

Safety Considerations

Formal safety data (specific warnings, contraindications, drug-drug interactions) are not available in the current Evidence Pack due to identified data gaps. The following reflects well-established retinoid pharmacology and the EMA Toctino SmPC:

Teratogenicity (critical): Alitretinoin is highly teratogenic. It is contraindicated in pregnancy and in women of childbearing potential who are not enrolled in a mandatory pregnancy prevention programme (PPP), which includes two forms of contraception and regular pregnancy testing. This safety constraint is particularly significant if acne — a condition disproportionately affecting young women — is the target indication.
Concomitant retinoids and vitamin A: Concurrent use with other retinoids or high-dose vitamin A supplements must be avoided due to additive toxicity risk (hypervitaminosis A syndrome: headache, pseudotumor cerebri, hepatotoxicity).

Please refer to the approved EMA Summary of Product Characteristics (SmPC) for Toctino for complete, authoritative prescribing and safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic case for alitretinoin in acne is biologically coherent — it shares the RAR/RXR retinoid pharmacology of isotretinoin, and a 1996 experimental study confirms comparable sebocyte-inhibitory activity. However, no dedicated clinical trials of alitretinoin specifically for acne have been conducted, isotretinoin is already well established as the definitive treatment for severe acne, and no clinical differentiation argument has been established. The Evidence Pack also identifies critical data gaps in MOA documentation and safety data, preventing a full S1 safety screening.

To proceed, the following is needed:

Retrieval of full mechanism of action data from DrugBank to formally document alitretinoin’s RAR/RXR receptor profile and distinguish it quantitatively from isotretinoin
A systematic review or direct comparative clinical study of alitretinoin vs isotretinoin for acne (efficacy, sebum suppression, tolerability, relapse rates)
Identification of a specific patient subpopulation that might benefit from alitretinoin’s dual RXR/RAR agonism (e.g., patients with coexisting severe hand eczema and acne, or isotretinoin-refractory cases)
Full safety profile review from the Toctino EMA SmPC, with particular attention to the pregnancy prevention programme implications for acne patients (predominantly young women of childbearing age)
Confirmation of actual dispensing availability in Denmark through Laegemiddelstyrelsen before initiating any Danish clinical investigation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.